Get my own profile
Public access
View all37 articles
5 articles
available
not available
Based on funding mandates
Co-authors
Prof. Gerard JP van WestenPI Computational Drug Discovery (Professor AI & Med Chem, Leiden University)Verified email at gjpvanwesten.nl
Andreas BenderKhalifa University; University of Cambridge; Pangea Bio; Universitatea Babeș-Bolyai; UMF ClujVerified email at ku.ac.ae
Gary TresadernComputational chemistry, Johnson & Johnson Innovative MedicineVerified email at its.jnj.com
Alexey "Alex" LugovskoyEIR, Atlas VentureVerified email at lugovskoy.org
Jörg Kurt WegnerDirector, In Silico Discovery, Janssen R&D, Cambridge, MA, USVerified email at its.jnj.com
Laura Perez-BenitoSenior Scientist Computational Chemistry JanssenVerified email at its.jnj.com
Eelke Bart LenselinkGalapagosVerified email at glpg.com
Woody ShermanPsivant TherapeuticsVerified email at psivant.com
Lindsey BurggraaffLeiden UniversityVerified email at lacdr.leidenuniv.nl
Thijs BeumingLatham Biopharm GroupVerified email at lathambiopharm.com
John P. OveringtonDrughunter.comVerified email at drughunter.com
Andrej SaliUniversity of California, San FranciscoVerified email at salilab.org
Michael T.M. Emmerich (Dr. rer. nat.)Professor in Multiobjective OptimizationVerified email at liacs.nl
PV CoveneyUCLVerified email at ucl.ac.uk
Bert UW MaesFull Professor, University of AntwerpVerified email at uantwerpen.be
Ivet BaharDirector, Laufer Center for Physical & Quantitative Biology, Stony Brook UniversityVerified email at pitt.edu
Thomas HankemeierProfessor of Analytical Biosciences, Leiden UniversityVerified email at lacdr.leidenuniv.nl
Eelke van der HorstThe HyveVerified email at thehyve.nl
Julio E. PeironcelyPhD student at Leiden UniversityVerified email at chem.leidenuniv.nl
Berthold WroblowskiSenior scientist,Janssen, Pharmaceutical Companies of Johnson and JohnsonVerified email at its.jnj.com